GROVES REGINA E
Known title: DirectorCIK: 0001653877
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FLGT compared to PRPO in cancer diagnostics sector. A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.
Transaction History
| ATRC | ▼ Sell | Open Market | 5,313 | $288K | 9/11/2026 | View on chart |
| ATRC | ▲ Buy | Grant | 6,144 | $0 | 5/18/2026 | View on chart |
| FLGT | ▲ Buy | Grant | 11,117 | $0 | 5/14/2026 | View on chart |
| ATRC | ▼ Sell | Open Market | 2,452 | $90K | 8/6/2025 | View on chart |
| ATRC | ▲ Buy | Grant | 5,401 | $0 | 5/19/2025 | View on chart |
| FLGT | ▲ Buy | Grant | 8,982 | $0 | 5/15/2025 | View on chart |
| FLGT | ▲ Buy | Grant | 4,000 | $0 | 5/16/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 7,788 | $0 | 5/13/2024 | View on chart |
| ATRC | ▲ Buy | Grant | 3,186 | $0 | 5/25/2023 | View on chart |
| FLGT | ▲ Buy | Grant | 4,000 | $0 | 1/3/2023 | View on chart |
| ATRC | ▲ Buy | Grant | 3,564 | $0 | 5/25/2022 | View on chart |
| ATRC | ▼ Sell | Open Market | 3,156 | $236K | 9/15/2021 | View on chart |
| ATRC | ▲ Buy | Open Market | 34 | $3K | 4/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BTIG raises AtriCure price target to $63
BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.
BTIG raises AtriCure price target to $63. BTIG raised its price target on AtriCure to $63. The new target sits above the current analyst consensus of $54.89 and exceeds the stock’s recent 52‑week high of $61.70. This adjustment may influence market expectations as the company trades near its recent support level of $27.47.